The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.

What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

Bexmarilimab is under clinical development by Faron Pharmaceuticals and currently in Phase II for Myelodysplastic Syndrome.

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my ...

BYON-4413 is under clinical development by Byondis and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase ...

Lenalidomide has proven efficacy and safety and has been shown to reduce transfusion requirements and reverse cytogenetic abnormalities in lower-risk myelodysplastic syndromes (MDS). However ...

AMeD syndrome is a severe genetic condition found in children that presents with accelerated aging, global developmental ...

While myelodysplastic syndromes (MDSs) are well-established conditions in adults, they are rather uncommon and difficult to classify in pediatric patients. On the other hand, myelodysplastic ...

Dr Andrew Ross, a medical doctor diagnosed with a life-threatening condition called Myelodysplastic Syndrome (MDS) is ...